What are the challenges in funding research and development of new antibiotics that may not be immediately profitable?

May 5, 2017 ... No clinical information was available about the patients from whom the cultures were taken. The identity and antimicrobial drug susceptibility ... CF therapy may represent an effective alternative to carbapenem treatment for patients with ESBL-EC bacteremia for empirical and definitive therapy in adult ... In this study we aimed to investigate in vitro activity of meropenem, ciprofloxacine and amikacin against ESBL-producing and non-producing blood isolates. These percentages are similar to our data. Prior antibiotic use was the risk factor for ESBL-producing Escherichia coli or Klebsiella pneumoniae infection [20]. The incidence of ESBL-producing E. coli bacteremia rose during the study period. By multiple logistic analysis, reported antibiotic use in the previous week was ... Dec 13, 2018 ... In the current study, ESBL-producing phenotypes were detected in 23% (n = 17) of urinary isolates, of which Escherichia coli accounts for 76.5% ... Jan 1, 2017 ... of hospitals with ESBL-KP infections throughout the study period, as 18 study hospitals. (69%) had ≥1 ESBL-KP infection in 2009, and 20 (77 ... hospitals among the many bacterial species of ESBL producers mentioned above, in this study we ... Testing; 16th Informational Supplement. CLSI document ... Jan 8, 2021 ... However, clinical information with respect to its utilization in infection caused by ESBL producers is limited. The aim of this study was a ... The aim of this study is to detect ESBL-producing Enterobacteriaceae by using rapid detection tests such as combined disk diffusion, ESBL E-test strips.